Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hylopan max is an ophthalmic solution containing a combination of sodium hyaluronate (0.15%) and dexpanthenol (2%). Sodium hyaluronate is a high-molecular-weight polysaccharide that acts as a mucomimetic lubricant and tear substitute, providing long-lasting relief for dry eyes by stabilizing the tear film and protecting the ocular surface. Dexpanthenol, a provitamin of B5 (pantothenic acid), promotes epithelial wound healing and provides additional moisturizing properties. This formulation is primarily used to alleviate postoperative discomfort following ocular surgeries, such as cataract extraction, and to treat symptoms of dry eye syndrome by enhancing hydration and supporting the regeneration of the corneal epithelium.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium hyaluronate + dexpanthenol.